

International Concurrent Workshop Clinical 3

RA comorbidity

Day 1 April 21, 15:00 - 16:10 Room 4

Chair: Yasuo Niki

Department of Orthopedic Surgery, Keio University, Japan

ICW-C3-1 Prevalence of comorbidities for patients with rheumatoid arthritis: A nationwide cross-sectional study

Chien-Chang Liao

School of Medicine, Taipei Medical University, Taipei, Taiwan

ICW-C3-2 Health Care Utilization Associated with Adverse Events among RA Patients Treated by TNF-alpha in Taiwan

Hsiao-Ling Kuo

Division of Rheumatology and Immunology, Mackay Memorial Hospital, Hsinchu, Taiwan

ICW-C3-3 Methotrexate toxicity among Filipino patients with rheumatoid arthritis included in the Rheumatoid Arthritis Database and Registry (RADAR)

Eliza Mia M Dejas

Section of Rheumatology, Department of Medicine, UP-Philippine General Hospital, Philippines

ICW-C3-4 Assessment of peripheral blood subsets related to spontaneous regression of Methotrexate associated lymphoproliferative disorder (MTX-LPD)

Shuntaro Saito

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

ICW-C3-5 Pulmonary barrier function rather than systemic immune state is crucial for the development and exacerbation of non-tuberculous mycobacterial (NTM) infection in patients with rheumatic diseases

Sayaka Takenaka

Division of Rheumatology, Toho University Ohashi Medical Center, Japan

ICW-C3-6 A risk analysis of Pneumocystis pneumonia in patient with rheumatoid arthritis by the National Database of Rheumatic Diseases by iR-net in Japan

Takahiro Nunokawa

Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan

ICW-C3-7 Possible preventive effect of salazosulfapyridine against development of *Pneumocystis* pneumonia in methotrexate-receiving patients with rheumatoid arthritis

Kenosuke Mizushina

Division of Rheumatology, Toho University Ohashi Medical Center, Japan